Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer.
collagen
colorectal cancer
extracellular matrix
metastasis
receptor
targeted therapy
tumor microenvironment
tyrosine kinase
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
12
2019
accepted:
23
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the leading causes of tumor-related death worldwide. While surgery can cure patients with early stage CRC, the 5-year survival rate is only 10% for patients with metastatic disease. Therefore, new anti-metastatic therapies are needed for this cancer. Metastatic spread defines the dissemination of cancer cells with tumor-initiating capacities from the primary tumor and their colonization of distinct organs, mainly the liver, for secondary tumor formation. Although the underlying mechanisms are not fully understood, components of the tumor microenvironment have gained strong interest. Among the known metastatic-promoting factors, collagens are extracellular matrix components that are deposited within the tumor, the tumor microenvironment, and at metastatic site(s), and are recognized to play essential roles during metastasis development. Here, we review recent findings on the metastatic role of the collagen receptors Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2) in CRC and discuss the therapeutic value of targeting these receptor tyrosine kinases in this cancer.
Identifiants
pubmed: 32117772
doi: 10.3389/fonc.2020.00125
pmc: PMC7028753
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
125Informations de copyright
Copyright © 2020 Lafitte, Sirvent and Roche.
Références
Structure. 2012 Apr 4;20(4):688-97
pubmed: 22483115
Int J Biol Sci. 2017 Nov 1;13(11):1450-1457
pubmed: 29209148
J Pathol. 2019 May;248(1):103-115
pubmed: 30666650
J Mol Biol. 2014 Jun 26;426(13):2457-70
pubmed: 24768818
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29438985
Cell. 2016 Jun 30;166(1):47-62
pubmed: 27368100
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
Elife. 2019 May 30;8:
pubmed: 31144616
Oncogene. 2018 Mar;37(13):1714-1729
pubmed: 29348456
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Commun. 2018 Nov 14;9(1):4783
pubmed: 30429478
Sci Adv. 2019 Feb 20;5(2):eaav2437
pubmed: 30801016
Nat Rev Clin Oncol. 2009 Jun;6(6):306-7
pubmed: 19483733
ACS Chem Biol. 2013 Oct 18;8(10):2145-50
pubmed: 23899692
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2007 Dec 14;131(6):1190-203
pubmed: 18083107
Cancer Discov. 2011 Jun;1(1):78-89
pubmed: 22328973
Nat Rev Cancer. 2003 May;3(5):362-74
pubmed: 12724734
Blood. 2007 Dec 1;110(12):4055-63
pubmed: 17720881
Mol Cell Oncol. 2018 Jul 23;5(4):e1465882
pubmed: 30250919
Anticancer Res. 2017 May;37(5):2587-2591
pubmed: 28476831
Elife. 2017 Jun 07;6:
pubmed: 28590245
Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53
pubmed: 18938156
Mol Cell. 1997 Dec;1(1):25-34
pubmed: 9659900
Cell Death Dis. 2018 Feb 15;9(3):271
pubmed: 29449544
Oncotarget. 2016 Jan 26;7(4):4093-109
pubmed: 26675259
Oncol Rep. 2019 Dec;42(6):2844-2854
pubmed: 31578591
J Med Chem. 2013 Apr 25;56(8):3281-95
pubmed: 23521020
Cancer Treat Rev. 2019 Jun;76:22-32
pubmed: 31079031
Cell Rep. 2016 Jun 14;15(11):2510-23
pubmed: 27264173
J Cell Biol. 2014 Nov 24;207(4):517-33
pubmed: 25422375
Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321
pubmed: 22366781
Mol Cell. 1997 Dec;1(1):13-23
pubmed: 9659899
Mol Cancer Res. 2018 Oct;16(10):1590-1600
pubmed: 29866925
J Mol Biol. 2019 Jan 18;431(2):368-390
pubmed: 30458172
Dig Dis Sci. 2014 Sep;59(9):2163-72
pubmed: 24711074
Matrix Biol. 2018 Aug;68-69:180-193
pubmed: 29605717
Cell Rep. 2017 Jan 31;18(5):1215-1228
pubmed: 28147276
J Exp Med. 2016 Oct 17;213(11):2315-2331
pubmed: 27697834
Cancer Res. 2017 Apr 15;77(8):1997-2007
pubmed: 28381547
Gut. 2012 Oct;61(10):1465-72
pubmed: 22071959
Nat Cell Biol. 2013 Jun;15(6):677-87
pubmed: 23644467
Cell. 2012 Dec 21;151(7):1457-73
pubmed: 23245941
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Int J Cancer. 2007 Dec 15;121(12):2808-14
pubmed: 17721919
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
EMBO Rep. 2005 Nov;6(11):1095-100
pubmed: 16211085
EMBO Rep. 2001 May;2(5):446-52
pubmed: 11375938
Nat Genet. 2019 Jul;51(7):1113-1122
pubmed: 31209394
Oncogene. 2013 Apr 4;32(14):1863-8
pubmed: 22641216
Nat Commun. 2019 May 13;10(1):2131
pubmed: 31086186
Cancers (Basel). 2018 Dec 19;10(12):
pubmed: 30572654
Mol Cell Biol. 2001 Apr;21(8):2906-17
pubmed: 11283268
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
J Biol Chem. 2002 May 24;277(21):19206-12
pubmed: 11884411
Leukemia. 2010 Jan;24(1):44-50
pubmed: 19890374
Am J Physiol Cell Physiol. 2019 Nov 1;317(5):C869-C880
pubmed: 31291143
Nat Med. 2016 Mar;22(3):270-7
pubmed: 26855149
Nat Cell Biol. 2011 Jan;13(1):49-58
pubmed: 21170030
Am J Cancer Res. 2019 Feb 01;9(2):449-454
pubmed: 30906642
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
J Biol Chem. 2000 Feb 25;275(8):5779-84
pubmed: 10681566
Front Pharmacol. 2016 Mar 14;7:55
pubmed: 27014069
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
Nat Commun. 2019 Nov 13;10(1):5139
pubmed: 31723138
Dig Dis. 2016;34(5):574-9
pubmed: 27332557
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7786-E7794
pubmed: 30061414
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10920-5
pubmed: 20534451
Int Rev Cell Mol Biol. 2014;310:39-87
pubmed: 24725424
Cancer Cell. 2013 Oct 14;24(4):410-21
pubmed: 24135279
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Clin Cancer Res. 2012 Feb 15;18(4):969-80
pubmed: 22223527
Mol Oncol. 2019 Sep;13(9):1855-1873
pubmed: 31116512
Cell Rep. 2017 Feb 14;18(7):1774-1790
pubmed: 28199848
Nat Biotechnol. 2019 Sep;37(9):1038-1040
pubmed: 31477924
J Biol Chem. 2005 Nov 25;280(47):39058-66
pubmed: 16186108